Trial Profile
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Antigen Dose-Escalation and Adjuvant Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Amezosvatein (Primary)
- Indications Herpes zoster
- Focus Adverse reactions
- Sponsors Curevo Vaccine
- 10 Feb 2021 Status changed from active, no longer recruiting to completed.
- 15 Sep 2020 According to a Curevo Vaccine media release, Curevo will present results from this Phase I trial on the 30th of September 2020 at the virtual World Vaccine Congress Washington conference.
- 15 Sep 2020 Results presented in a Curevo Vaccine media release.